Search results for " vaccine"

showing 10 items of 680 documents

Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for …

2015

Background Up-to-date evidence on levels and trends for age-sex-specific all-cause and cause-specific mortality is essential for the formation of global, regional, and national health policies. In the Global Burden of Disease Study 2013 (GBD 2013) we estimated yearly deaths for 188 countries between 1990, and 2013. We used the results to assess whether there is epidemiological convergence across countries. Methods We estimated age-sex-specific all-cause mortality using the GBD 2010 methods with some refinements to improve accuracy applied to an updated database of vital registration, survey, and census data. We generally estimated cause of death as in the GBD 2010. Key improvements included…

MaleAgingPediatricsNutrition and DiseaseDatabases FactualDisease030204 cardiovascular system & hematologyGlobal HealthMedical and Health SciencesDOUBLE-BLIND0302 clinical medicineAdolescent; Adult; Aged; Aged 80 and over; Cause of Death; Child; Child Mortality; Child Preschool; Databases Factual; Female; Global Health; Humans; Infant; Infant Newborn; Life Expectancy; Life Tables; Male; Middle Aged; Models Statistical; Mortality; Sex Distribution; Young AdultModelsVoeding en ZiekteCause of DeathEpidemiologyGlobal health80 and over2.2 Factors relating to the physical environmentLife Tables030212 general & internal medicineAetiologyChildINFLUENZAE TYPE-B11 Medical and Health SciencesCause of deathPediatricAged 80 and overPLACEBO-CONTROLLED-TRIALLife TableMortality rateMedicine (all)1. No povertyGeneral MedicineCHILDHOOD PNEUMONIAMiddle AgedStatistical3. Good healthInfectious DiseasesChild PreschoolPNEUMOCOCCAL CONJUGATE VACCINEChild MortalityFemaleInfectionLife Sciences & BiomedicineHumanAdultmedicine.medical_specialtyAdolescentINTEGRATED APPROACHCHILDREN YOUNGER187 COUNTRIESDatabase03 medical and health sciencesDatabasesYoung AdultMedicine General & InternalLife ExpectancyGeneral & Internal MedicinemedicineLife ScienceHumansMortalitySex DistributionPreschoolFactualVLAGAgedScience & TechnologyModels Statisticalbusiness.industryPreventionPOPULATION HEALTHInfant NewbornENTERIC MULTICENTERInfantGBD 2013 Mortality and Causes of Death CollaboratorsNewbornVerbal autopsyChild mortalityGood Health and Well BeingLife expectancyRISK-FACTORSbusiness2.4 Surveillance and distributionDemographyModel
researchProduct

Management of anaphylaxis due to COVID-19 vaccines in the elderly

2021

Submitted by (omml@ubi.pt) on 2021-07-05T10:47:24Z No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Approved for entry into archive by Pessoa (pfep@ubi.pt) on 2021-07-05T10:49:11Z (GMT) No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Rejected by Pessoa (pfep@ubi.pt), reason: Rever os nomes dos autores. Depois da correção é só voltar a submeter. on 2021-07-05T10:54:19Z (GMT) Submitted by (omml@ubi.pt) on 2021-07-05T11:52:24Z No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffab…

MaleAllergyPediatricsEaaci Position PaperCOVID-19 vaccinesolder (adultsGUIDELINES0302 clinical medicine[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesMedicine and Health SciencesImmunology and AllergyMedicine030212 general & internal medicineComputingMilieux_MISCELLANEOUSGeriatricsMESH: AgedRISKVaccines[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseasespeople)EPINEPHRINEEpinephrine[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/VirologyCOVID -19 vaccinesAnaphylaxismedicine.drugolder (adults/people)medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)MESH: Covid-19MESH: EpinephrineImmunologyadrenaline; anaphylaxis; COVID-19 vaccines; older (adults/people); Aged; COVID-19 Vaccines; Epinephrine; Humans; Male; SARS-CoV-2; Anaphylaxis; COVID-19Settore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemDiabetes mellitusAnaphylaxis/etiologyanaphylaxisHumansMESH: SARS-CoV-2[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/ParasitologyCOVID‐19 vaccinesOlder - Adults/peopleAsthmaAgedMESH: Humansadrenalinebusiness.industrySARS-CoV-2adrenaline anaphylaxis COVID-19 vaccines older (adults/people)COVID-19medicine.diseaseObesity[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologyMESH: MaleMESH: AnaphylaxisOlder3121 General medicine internal medicine and other clinical medicinebusinessMESH: Covid-19 vaccines030215 immunologyAllergy
researchProduct

Editorial Comment to Infectious aortic aneurysms occurring 1 year after bacillus Calmette–Guérin bladder instillation therapy

2014

Editorial Comment

MaleBacillus (shape)Pathologymedicine.medical_specialtybiologybusiness.industryUrologybiology.organism_classificationSettore MED/24 - UrologiaBCG VaccinemedicineHumansbusinessAneurysm InfectedAortic Aneurysm AbdominalBladder Cancer BCG aortic aneurysm
researchProduct

Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (Me…

2012

The present extension study, conducted in children originally vaccinated at 12–14 mo or 3–5 y of age, assessed antibody persistence and immune memory induced by an investigational tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT). In the original study, participants were randomized to receive one dose of MenACWY-TT or licensed age-appropriate meningococcal control vaccines. Fifteen months post-vaccination, all participants underwent serum sampling to evaluate antibody persistence and participants previously vaccinated as toddlers received a polysaccharide challenge to assess immune memory development.   Exploratory comparisons showed that (…

MaleBlood Bactericidal ActivityImmunologyPriming (immunology)Meningococcal VaccinesMeningococcal vaccineNeisseria meningitidismedicine.disease_causeimmune memoryPersistence (computer science)meningococcal vaccinechildrenConjugate vaccinemedicineHumansImmunology and AllergytoddlersPharmacologyMicrobial Viabilitybiologybusiness.industryTetanusNeisseria meningitidisToxoidInfantSpecial Focus Short Reportpersistencemedicine.diseaseAntibodies BacterialVirologyChild PreschoolImmunologybiology.proteinFemaleAntibodytetanus toxoidbusinessImmunologic MemoryHuman Vaccines & Immunotherapeutics
researchProduct

Long-term pertussis-specific immunity after primary vaccination with a combined diphtheria, tetanus, tricomponent acellular pertussis, and hepatitis …

2001

ABSTRACT The aim of this study was to compare pertussis-specific humoral and cellular immunity in children 5 years after a primary vaccination with a combined diphtheria, tetanus, tricomponent acellular pertussis, and hepatitis B vaccine (DTaP-HBV; InfanrixHepB; SmithKline Beecham) with immunity after natural infection. The subjects were 38 children aged 5 to 6 years who received DTaP-HBV at 3, 5, and 11 months of life and 21 subjects of similar ages and sex who acquired pertussis in the first year of life. Immunoglobulin G (IgG) antibody titers against Bordetella pertussis antigens, peripheral blood mononuclear cell-specific proliferation, and the secretion of cytokines were evaluated. Aft…

MaleBordetella pertussisCellular immunityTime FactorsHepatitis B vaccineWhooping CoughImmunologyMicrobiologyBordetella pertussisAntibodiesInterferon-gammaImmunitymedicineHumansHepatitis B VaccinesSingle-Blind MethodVaccines CombinedLymphocytesChildPreschoolDiphtheria-Tetanus-Pertussis VaccineWhooping coughHaemophilus VaccinesVaccinesbiologyVaccines; Combined; Interferon-gamma; Humans; Whooping Cough; Hepatitis B Vaccines; Child; Lymphocytes; Diphtheria-Tetanus-Pertussis Vaccine; Vaccination; Preschool; Bordetella pertussis; Single-Blind Method; Interleukin-2; Antibodies; Bacterial; Haemophilus Vaccines; Interleukin-4; Interleukin-5; Time Factors; Male; Female; Cell DivisionCombinedTetanusbusiness.industryDiphtheriaCELL-MEDIATED-IMMUNITYVaccinationBacterialbiology.organism_classificationmedicine.diseaseAntibodies BacterialVirologyVaccinationInfectious DiseasesChild PreschoolMicrobial Immunity and VaccinesImmunologyInterleukin-2FemaleParasitologyInterleukin-4Interleukin-5businessCell Division
researchProduct

Reactogenicity of a three-dose pertussis acellular vaccine catch-up in children 21-40 months of age

1999

Abstract The reactogenicity of a three-dose catch-up acellular pertussis (aP) immunization of children at 21–40 months of age was evaluated. Vaccination was well-tolerated: fever ≥38°C was reported after 5% of administered doses and local reactions after 14–15%. The onset of adverse events was not associated with age at vaccination, interval between doses or previous presence of antibodies against pertussis, whereas injection in sites other than the buttock and presence of the same symptom after a previous dose were associated with higher reactogenicity. Because of the good safety profile of primary aP immunization in children >1 year of age, catch-up vaccination campaigns could be consider…

MaleBordetella pertussisPediatricsmedicine.medical_specialtyAgingDose-Response Relationship ImmunologicBordetella pertussisMedicineHumansAdverse effectWhooping coughImmunization SchedulePertussis VaccineReactogenicityGeneral VeterinaryGeneral Immunology and Microbiologybiologybusiness.industryVaccinationPublic Health Environmental and Occupational HealthInfantbiology.organism_classificationmedicine.diseaseAntibodies BacterialVaccinationInfectious DiseasesImmunizationEl NiñoChild PreschoolImmunoglobulin GToxicityImmunologyMolecular MedicineFemalebusiness
researchProduct

Detection of delayed vaccinations: a new approach to visualize vaccine uptake

2002

For the prevention of pertussis and invasive Haemophilus influenzae type b (Hib) infections, each with a peak for mortality and serious complications in the first year of life, early vaccination is important and needs adequate monitoring. In a 1999 national coverage survey the timing of uptake of these vaccines in German children was therefore assessed conventionally at defined age thresholds and with a new adaptation of the Kaplan–Meier (KM) method estimating immunization uptake over time by 1 minus the survival function s(t). Only 6% and 9% of children were vaccinated against pertussis and Hib in accordance with the national recommended primary vaccination schedule. Coverage levels for th…

MaleBordetella pertussisPediatricsmedicine.medical_specialtyHaemophilus InfectionsTime FactorsWhooping CoughEpidemiologyHaemophilus influenzae typePrimary vaccinationFirst year of lifemedicine.disease_causeHaemophilus influenzaeGermanymedicineHumansImmunization ScheduleWhooping coughHaemophilus VaccinesPertussis VaccinebiologyImmunization Programsbusiness.industryInfant NewbornInfantmedicine.diseasebiology.organism_classificationHealth SurveysVaccinationInfectious DiseasesImmunizationPopulation SurveillanceImmunologyFemalebusinessResearch ArticleEpidemiology and Infection
researchProduct

SARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study

2021

Abstract Background Preoperative SARS-CoV-2 vaccination could support safer elective surgery. Vaccine numbers are limited so this study aimed to inform their prioritization by modelling. Methods The primary outcome was the number needed to vaccinate (NNV) to prevent one COVID-19-related death in 1 year. NNVs were based on postoperative SARS-CoV-2 rates and mortality in an international cohort study (surgical patients), and community SARS-CoV-2 incidence and case fatality data (general population). NNV estimates were stratified by age (18–49, 50–69, 70 or more years) and type of surgery. Best- and worst-case scenarios were used to describe uncertainty. Results NNVs were more favourable in su…

MaleCOVID-19 Vaccinesafe surgery; vaccination modelling; COVID-19Vascular damage Radboud Institute for Health Sciences [Radboudumc 16]MULTICENTERComorbidity030230 surgery0302 clinical medicinephase 3 clinical trial (topic)Case fatality rateProspective StudiesSARS-CoV-2 Vaccination Safe surgeryCOVID-19/epidemiologySARS-CoV-2 ; vaccination ; safe surgeryeducation.field_of_studycase fatality rateVaccinationVaccinationAdolescent; Adult; Aged; COVID-19; COVID-19 Vaccines; Comorbidity; Elective Surgical Procedures; Female; Humans; Male; Middle Aged; Postoperative Complications; Preoperative Period; Prospective Studies; SARS-CoV-2; Vaccination; Young Adulthealth care policyElective Surgical Procedures030220 oncology & carcinogenesisvaccination modellingPreoperative PeriodCOVID-19; SARS-CoV-2; cancer; vaccination; outcome; mortality; infection; modellingCohort studyprospective studyHumanmedicine.medical_specialtyArticle03 medical and health sciencesSARS-CoV-2 vaccinationSDG 3 - Good Health and Well-beingCOVID-19 Vaccines/pharmacologyHumansVaccination/methodsElective surgeryeducationAgedScience & TechnologyElective Surgical Procedureadult; aged; Article; cancer grading; cancer surgery; case fatality rate; computer assisted tomography; elective surgery; female; follow up; health care policy; human; incidence; infection rate; infection risk; major clinical study; male; middle aged; mortality; outcome assessment; phase 3 clinical trial (topic); preoperative care; prospective study; sensitivity analysis; seroprevalence; Severe acute respiratory syndrome coronavirus 2; vaccination; young adult; COVID-19; COVID-19 Vaccines; Comorbidity; Elective Surgical Procedures; Postoperative Complications; Preoperative Period; SARS-CoV-2; Vaccination; surgery.Cura preoperatòriamajor clinical studymortalityinfectionProspective StudieincidenceSurgeryHuman medicinePostoperative Complication610 Medizin und GesundheitAcademicSubjects/MED00910Settore MED/18 - CHIRURGIA GENERALESettore MED/29 - CHIRURGIA MAXILLOFACCIALEcomputer assisted tomographyESTUDOS PROSPECTIVOSsurgerysafe surgeryPostoperative Complicationssensitivity analysisSevere acute respiratory syndrome coronavirus 2preoperative careVacunacióProspective cohort studyseroprevalenceIncidence (epidemiology)covidElective Surgical Procedures/methodsMiddle Agedcancer gradingCOVID vaccinationoutcome/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingSARS-CoV-2; vaccination; surgeryOriginal ArticleFemalecancer surgeryAcademicSubjects/MED00010Life Sciences & BiomedicineAdultCOVID-19 VaccinesAdolescentinternational prospective cohort studyPostoperative Complications/prevention & controlPopulationinfection rateSARS-CoV-2/immunologyNOmodellingYoung Adultmedicinefollow upcancerddc:610infection riskoutcome assessmentLS7_4business.industrySARS-CoV-2Number needed to vaccinatePreoperative careCOVID-193126 Surgery anesthesiology intensive care radiologySettore MED/18Reconstructive and regenerative medicine Radboud Institute for Health Sciences [Radboudumc 10]elective surgeryEmergency medicinebusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyThe British Journal of Surgery
researchProduct

Complete tumor prevention by engineered tumor cell vaccines employing nonviral vectors.

2004

We report that 100% mice survival after tumor challenge is achieved with cytokine-engineered cells employing nonviral lipoplexes and without using viral vectors. We describe this effect with cytokine-secreting tumor cell vaccines, based on cell clones or fresh transfected cells. Tumor cells were transfected with murine granulocyte-macrophage colony-stimulating factor (GM-CSF) or IL-4 plasmids employing the cationic lipid DOTAP, were irradiated (150 Gy) and kept frozen until use. The transfection efficacy was analyzed by qRT-PCR and flow cytometry. Vaccination induced potent antitumor rejection, resulting in 100% mice survival. Furthermore, the antitumor immunity was long lasting, since a tw…

MaleCancer ResearchSkin NeoplasmsGenetic enhancementCellGenetic VectorsAntineoplastic AgentsBiologyCancer VaccinesViral vectorFlow cytometryMicemedicineAnimalsMolecular BiologyMelanomaInterleukin 4medicine.diagnostic_testReverse Transcriptase Polymerase Chain ReactionMelanomaGranulocyte-Macrophage Colony-Stimulating FactorTransfectionGenetic TherapyNeoplasms Experimentalmedicine.diseaseFlow CytometryVirologySurvival AnalysisMice Inbred C57BLmedicine.anatomical_structureGranulocyte macrophage colony-stimulating factorMolecular MedicineFemaleInterleukin-4Genetic Engineeringmedicine.drugCancer gene therapy
researchProduct

INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A multicenter prospective observational study (INVIDIa-2)

2021

BackgroundUntil now, no robust data supported the efficacy, safety and recommendation for influenza vaccination in patients with cancer receiving immune checkpoint inhibitors (ICIs).MethodsThe prospective multicenter observational INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors (INVIDIa-2) study investigated the clinical effectiveness of influenza vaccination in patients with advanced cancer receiving ICIs, enrolled in 82 Italian centers from October 2019 to January 2020. The primary endpoint was the time-adjusted incidence of influenza-like illness (ILI) until April 30, 2020. Secondary endpoints regarded ILI severity and vaccine safety.ResultsThe study enrolle…

MaleCancer ResearchTime Factors2435immunogenicity0302 clinical medicineRisk FactorsNeoplasmsvaccineClinical endpointImmunology and Allergyantibodiesantibodies; immunization; immunogenicity; immunotherapy; neoplasm; vaccination; vaccine1506Prospective Studies030212 general & internal medicineImmune Checkpoint InhibitorsRC254-282Clinical/Translational Cancer ImmunotherapyAged 80 and overIncidenceIncidence (epidemiology)virus diseasesNeoplasms. Tumors. Oncology. Including cancer and carcinogensMiddle AgedVaccinationTreatment OutcomeItalyOncologyInfluenza Vaccines030220 oncology & carcinogenesisMolecular MedicineFemaleimmunotherapyAdultmedicine.medical_specialtyInfluenza vaccineImmunologyVaccine EfficacyimmunizationRisk AssessmentYoung Adult03 medical and health sciencesInternal medicineInfluenza HumanmedicineHumansLung cancerAdverse effectAgedPharmacologybusiness.industryCancermedicine.diseasevaccinationImmunizationbusinessneoplasm
researchProduct